The Precision Peptide Company Inc. is a biotechnology firm specializing in the development and production of high-purity peptides for therapeutic and research applications. The company synthesizes custom peptides tailored for medical treatments, pharmaceutical research, and clinical studies, with a focus on areas including endocrinology, immunology, and oncology. Its core offerings encompass custom peptide synthesis services, catalog peptides for standard research needs, and advanced peptide modifications such as cyclization and labeling to enhance stability and functionality. The Precision Peptide Company Inc. serves academic institutions, biotech firms, and pharmaceutical companies, providing scalable solutions ranging from small-scale research quantities to large-scale manufacturing for preclinical and clinical trials. By utilizing solid-phase peptide synthesis technology and maintaining rigorous quality controls, the company supports innovation in peptide-based therapeutics and diagnostics. Headquartered in Vancouver, British Columbia, The Precision Peptide Company Inc. operates as a key player in the peptide therapeutics market, contributing to advancements in targeted drug delivery and personalized medicine.
Markedsdata leveret af TwelveData og Morningstar